Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Lichen Planus, OralLichen Planus, MucosalOral Lichen Planus

Interventions

DRUG

Baricitinib 4 milligram Oral Tablet

4 milligrams once daily

Trial Locations (1)

RECRUITING

UNC Dermatology and Skin Cancer Center, Chapel Hill

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER